November 25, 2019 07:00 AM ESTUpdated 06:42 PM
R&D
China

Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

Jason Mast

Editor

With an eye on a swelling Chi­nese mar­ket, Roche un­veiled Phase III da­ta show­ing a com­bi­na­tion of Tecen­triq, its im­munother­a­py, and Avastin could help pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times